MAbSilico is a deeptech company from French academic research labs. Founded in 2017, MAbSilico is a software editor with the vision to accelerate the development of therapeutic antibody focusing on the early stage development to provide leads in a few years today to a few weeks.

MAbSilico is developing a software suite combining algorithms and databases based on 20 years of proven research and protected by patent. Our Artificial Intelligence and machine learning -driven tools cover two key steps of the early-stage antibody development; the lead identification and the lead characterization.

Our aim is to help customers to select more effectively the best candidate, secure more efficiently their IP, by only using the DNA sequences of the antibodies.

For epitope determination or off-targets prediction get ready to use the deeptech driven solutions of MAbSilico to select your best leads.